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Abstract 
Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. 
Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To 
overcome drug resistance, we explored a promising approach based on the use of 5-aza-2′-
deoxycytidine (AZA), a demethylating agent, in combination with the mTOR inhibitor 
everolimus in MTC cells (MZ-CRC-1 and TT). This combined treatment showed a strong 
synergistic antiproliferative activity through the induction of apoptosis. The effect of 
everolimus and/or AZA on genome-wide expression profiling was evaluated by Illumina 
BeadChip in MZ-CRC-1 cells. An innovative bioinformatic pipeline identified four potential 
molecular pathways implicated in the synergy between AZA and everolimus: PI3K-Akt 
signaling, the neurotrophin pathway, ECM-receptor interaction and focal adhesion. Among 
these, the neurotrophin signaling pathway was most directly involved in apoptosis, through 
the overexpression of NGFR and Bax genes. The increased expression of genes involved in 
the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus 
was validated by western blotting in MZ-CRC-1 cells. Interestingly, addition of a neutralizing 
anti-NGFR antibody abolished the synergistic cytotoxic activity between AZA and 
everolimus. These results open a new therapeutic scenario for MTC and potentially other 
neuroendocrine tumors, where therapy with mTOR inhibitors is currently approved. 
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1. Introduction 
Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating from parafollicular C 
cells and it results highly resistant to chemo- and radiotherapy (Vitale et al., 2001). The 
hyper-activation of the PI3K/Akt/mTOR cascade has a relevant role in the pathogenesis and 
progression of MTC. In fact, most of the pro-oncogenic effects of RET and RAS mutations 
are modulated by the activation of PI3K/Akt/mTOR pathway (Lyra et al., 2014; Manfredi et 
al., 2015). Few preliminary studies showed promising antitumor effects of mTOR inhibitors, 
such as everolimus, in MTC (Druce et al., 2012; Faggiano et al., 2012; Heilmann et al., 2016; 
Lim et al., 2013). A recent phase II study, assessing efficacy and tolerability of everolimus on 
tumor progression in patients with advanced thyroid cancer, showed stable disease in 5 out of 
7 (71%) patients with MTC and a low toxicity profile for everolimus (Schneider et al., 2015). 
Although everolimus has been reported to inhibit cell proliferation and angiogenesis in 
several human tumors, long-term treatment with mTOR inhibitors can be frustrated by the 
induction of resistance. Moreover, the anticancer effect of everolimus may be limited because 
of the intrinsic lack of inhibition on mTORC2 and the activation of survival pathways in 
cancer cells (Chan and Kulke, 2014). On this basis, anticancer treatment with everolimus as 
monotherapy may not be optimal, supporting the rationale for a combined treatment approach 
with other targeted agents. 
Epigenetic alterations, including dysregulated protein acetylation and DNA methylation, 
affect gene expression, and contribute to tumorigenesis in several tumors (Hervouet et al., 
2013; Walenkamp et al., 2014), including MTC (Vitale et al., 2016). PI3K/Akt/mTOR 
pathway is frequently deregulated in several malignancies through epigenetic alterations 
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(Goel et al., 2004). Epigenetic alterations appear to be also implicated in the development of 
resistance to mTOR inhibitors (Bihani et al., 2015; Juengel et al., 2012). In fact, histone 
deacetylase inhibitors are able to re-sensitize renal carcinoma cells to mTOR inhibitors 
(Bihani et al., 2015; Juengel et al., 2012; Juengel et al., 2014). However, most of the 
epigenetic mechanisms of resistance to mTOR inhibitors, particularly those concerning 
aberrant DNA methylation, remain poorly defined. 
In the present manuscript we have explored a novel approach to potentiate the antitumor 
activity of everolimus, based on the use of 5-aza-2′-deoxycytidine (AZA), a well established 
demethylating agent, in MTC. 
 
2. Materials and methods 
2.1 Cell lines and reagents  
Everolimus and AZA were kindly supplied by Novartis Pharma (Basel, Switzerland) and 
Sigma-Aldrich (St. Louis, USA), respectively. Both drugs were dissolved in DMSO and 
stored at -20°C. Human MTC cell lines (MZ-CRC-1 and TT) were provided from Prof. Lips 
(Utrecht, The Netherlands). Both cell lines were cultured at 37°C and 5% CO2 in F-12 with 
Kaighn’s Modification medium supplemented with 10% foetal bovine serum, 2 nM 
glutamine and 10
5
 U/l penicillin-streptomycin. HEK-293 (ATCC) human embryonic kidney 
cell line was cultured at 37°C and 5% CO2 in DMEM high glucose medium, without sodium 
pyruvate, supplemented with 10% foetal bovine serum, 2 nM glutamine and 10
5
 U/l 
penicillin-streptomycin. 
 
2.2 Cell viability assessment 
MTC cells were plated in 96-well plates (3x10
4
 cells per well) and treated with various 
concentrations of compounds (range 10
-1
-10
2 
nM for everolimus, 10
-3
-10
5 
nM for AZA). Cells 
growing in drug free medium and vehicle treated were used as control. After 3 days, medium 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
and drugs were replaced. After 6 days viability of cells was measured by the MTT assay (3-
(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium), as previously described (Vitale et al., 
2012). Under the same conditions the in vitro toxicity of everolimus and AZA at synergistic 
concentrations was examined through MTT assay in HEK-293 cells. 
 
2.3 Drug combination studies 
MTC cells were seeded in 96-well plates with medium without and with everolimus and/or 
AZA at different concentrations. After 3 days, medium and compounds were refreshed. Cell 
viability was evaluated after 6 days of treatment using MTT assay. Three combinations were 
tested for each schedule: equiactive doses of the two agents (IC50), higher relative doses of 
everolimus (IC75 of everolimus/IC25 of AZA) and higher relative doses of AZA (IC25 of 
everolimus/IC75 of AZA). Assessment of synergistic interaction between drugs was 
performed with CalcuSyn software (Biosoft, Ferguson, MO). Combination index (CI) values 
of <1, 1, and >1 are suggestive of synergy, additivity and antagonism, respectively (Chou et 
al., 1994; Chou and Talalay, 1984). We also evaluated: the dose reduction index (DRI), 
providing the magnitude of how much the dose of each drug in a synergistic combination 
may be reduced at a given effect level compared with the doses of each drug alone; the 
potentiation factor (PF), deﬁned as the ratio of the IC50 of either everolimus and AZA alone 
to the IC50 of everolimus and AZA in combination. 
 
2.4 Cell cycle analysis 
Cells were plated in 6-well plates (3x10
5
 cells/well) in duplicate with medium without 
(control group) and with everolimus and/or AZA. After 3 days, medium and drugs were 
refreshed. After 6 days, cells were collected, stained with propidium iodide (PI) (Sigma-
Aldrich, St. Louis, MO, USA), and analyzed using a FACScalibur flow cytometer (Becton 
Dickinson, Belgium) and CellQuest Pro Software, as previously described (Vitale et al., 
2007). 
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2.5 Flow cytometric analysis of apoptosis 
Cells were plated in 6-well plates and incubated with everolimus and/or AZA, as reported in 
the section of cell cycle analysis. After 6 days of treatment, cells were collected and stained 
with Annexin V-FITC (BD Pharmingen, San Diego, USA) and PI, and all samples were 
analyzed with FACScalibur, as previously reported (Vitale et al., 2006).  
 
2.6 Western blot  
MZ-CRC-1 cells were plated in 6-well plates and incubated with everolimus and/or AZA, as 
previously reported. After 6 days of treatment, cells were scraped, washed in PBS and 
resuspended in RIPA lysis buffer. Lysates were centrifuged, and protein analysis was 
conducted on supernatant. Cell extracts (50 μg/lane) were separated on NuPage 4-12% Bis-
Tris Gels (Life Technologies) and transferred with iBlot System (Life technologies). 
Membranes were blocked with 5% milk TBS-T and incubated with specific antibodies 
overnight at 4 °C: anti-caspase-3 and PARP, anti-cleaved caspase and PARP, anti-Bcl2, anti-
Bax, anti-mTOR, anti-phospho-mTOR (Ser2448), anti-4E-BP1, anti-phospho-4E-BP1 (Ser 
65), anti-MAPK10, anti-phospho-MAPK8/9/10 (Thr183/Tyr185), anti-phospho-p53 (Ser15) 
(Cell Signaling Technology, Beverly, MA) and anti-NGFR (Sigma-Aldrich, St. Louis, MO, 
USA). Blots were detected by the Luminata Forte ECL kit (Millipore) after incubation with 
HRP conjugated mouse and rabbit secondary antibodies (dilution 1:1,000 for anti-MAPK10, 
anti-phosphoMAPK8/9/10 and anti-phospho-p53; 1:5,000 for anti-caspase-3; and 1:10,000 
for other antibodies) and then exposed to X-ray film. Bands of interest were quantified 
through ImageJ software version 1.47. Results were normalized against the level of actin 
expression in each sample and the intensities of the bands were expressed as arbitrary units 
when compared to those of the untreated cells. 
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2.7 Gene expression profiling 
MZ-CRC-1 cells were seeded in 6-well plates and treated with everolimus and/or AZA, as 
previously reported. After 6 days, total RNA was extracted using Trizol Reagent (Life 
Technologies) and purified by RNeasy Mini Kit (Qiagen, Hilden, Germany). Amplification 
Grade DNase I (Life Technologies) was used to eliminate residual genomic DNA from RNA 
samples. Samples with an A260/A280 ratio falling in the range 1.8-2.1 were used for 
experiments. 
The Illumina TotalPrep RNA Amplification kit (Ambion, Foster City, USA) was employed 
using 200 ng of total RNA as starting material. Labelled cRNA (750 ng) was hybridized to 
human HT-12 v3 BeadChip arrays (Illumina, San Diego, USA) according to the 
manufacture's recommendation. Fluorescent images were obtained with a BeadArray reader 
and processed with the BeadScan software. 
 
 
2.8 Microarray gene expression analysis 
Significance Analysis of Microarray (SAM) was employed to identify differentially 
expressed genes (DEGs) by comparing the expression value of each gene between every 
group of treatment vs the untreated control, as previously described (Tusher et al., 2001). All 
the delta values were selected in order to provide a false discovery rate (FDR) <0.05. Once 
determined the DEGs, the next step was to discover which biological pathways were 
associated to the list of DEGs through Signaling Pathway Impact Analysis (SPIA) (Tarca et 
al., 2009), an algorithm of third generation that takes in consideration not only the identity of 
the genes but also the topology of the pathway. These aspects were reported by the 
probability values: pPERT (reflecting the amount of perturbation measured in each pathway) 
and pNDE (probability of obtaining a number of DEGs on the given pathway at least as large 
as the observed one). These two types of evidence, pPERT and pNDE, were finally combined 
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into one global probability value, pGFdr, which was used to rank the pathways and to test the 
research hypothesis that the pathway was significantly involved in the condition under the 
study. To refine the SPIA analysis, a downstream analysis based on the structural equation 
modeling (SEM) was performed (Pepe and Do, 2015; Pepe and Grassi, 2014). The method 
consists in the understanding how the DEGs, source of perturbation, propagated the 
perturbation in the biological network composed by the significant pathways. The module 
was obtained by the detection and fusion in a unique model of all directed shortest paths that 
put in communication the DEGs present in the significant pathways. This allowed: 1) to 
overcome the limits of the classical pathway analysis that considers the pathways as separate 
entities; 2) to detect the biological network where the drug modules are searched.  
 
2.9 DNA preparation and Infinium Methylation 450K array 
MZ-CRC-1 cells were plated in 6-well plates and treated with everolimus and/or AZA, as 
previously reported. After 6 days, total DNA was extracted using the DNeasy Blood & Tissue 
Kit (Qiagen, Germany). Quality control and quantification of DNA were performed before 
and after bisulphite conversion. DNA was quantified with NanoDrop (NanoDrop Products 
Thermo Scientific Wilmington, DE) and by fluorometric reading (Quant-iT™ PicoGreen® 
dsDNA Assay Kit); quality was assessed by visualisation of genomic DNA on 1% agarose 
gel electrophoresis. Only not fragmented DNA samples and with a concentration higher than 
50 ng/μl were subsequently processed. The genomic DNA was treated with sodium bisulfite 
using the EZ DNA Methylation Kit ™ (Zymo Research); the technique requires only 500 ng 
of input DNA. Four microliters of bisulfite-converted DNA were used for hybridization on 
Infinium HumanMethylation 450K BeadChip, according to Illumina’s standard protocol. 
Data were acquired through Illumina HiScan SQ scanner. Image intensities were extracted 
using GenomeStudio software v2010.3. The methylation score for each CpG site was 
represented as β values according to the fluorescent intensity ratio between methylated and 
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unmethylated probes. β values may range between 0 (completely unmethylated) and 1 
(completely methylated). Illumina Methylation 450K raw data were analysed using the 
RnBeads analysis software package (Assenov et al., 2014). Sites overlapping SNPs were 
firstly removed from the analysis as well as probes on sex chromosomes. Probes and samples 
of highest impurity were removed from the dataset using the Greedycut algorithm. We have 
considered every β value to be unreliable when its corresponding detection p-value was not 
below the threshold (T=0.05). The background was subtracted using the methylumi package 
(method "noob"). The signal intensity values were normalized using the SWAN 
normalization method, as implemented in the minfi package (Aryee et al., 2014). The 
“Shapiro.test” function provided in the R package “stats” was applied to test normality 
among variables. The “kruskal.test” function provided in the R package “stats” was used to 
test differences among treated and untreated groups for all non-parametric data. DunnTest 
provided in the R package “ dunn.test” has been applied as post-hoc test. 
 
2.10 Statistical analysis 
All experiments were performed at least 3 times. Statistical differences among groups were 
ﬁrst evaluated by the ANOVA test, followed by post-hoc test (Newman-Keuls). A P value < 
0.05 was considered significant. The values reported in the ﬁgures represent the mean ± 
standard error of the mean. For statistical analysis GraphPad Prism 5.0 was used. 
 
3. Results 
3.1 Pharmacological combination between everolimus and AZA on cell proliferation 
In MZ-CRC-1 cells the combination of everolimus and AZA was highly synergistic when 
either the two drugs were used with lower concentrations of everolimus (IC25 everolimus:IC75 
AZA) or with equitoxic concentrations (IC50 everolimus:IC50 AZA) (table 1, figure 1). The 
DRI50 (DRI calculated for 50% cell survival) was 8.8 for everolimus and 101 for AZA (when 
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drugs were used at IC25 everolimus:IC75 AZA), 4.3 for everolimus and 590 for AZA (at 
equitoxic concentrations) (table 1). 
In TT cells a synergistic activity was similarly detected when lower concentrations of 
everolimus were adopted (IC25 everolimus:IC75 AZA), while antagonistic effects were 
observed with relative higher concentrations of everolimus (IC75 everolimus:IC25 AZA) (table 
1, figure 1). 
The optimal results (lowest CI values) were obtained when the two drugs were used at lower 
doses of everolimus in MZ-CRC-1 cells. Therefore, we have performed subsequent 
experiments using 2.1 nM (IC25) of everolimus and/or 1.4x10
2
 nM (IC75) of AZA in MZ-
CRC-1 cells. 
 
 
3.2 In vitro toxicity assessment 
The effect of drug combination on the cell viability of HEK-293 cell line, derived from 
human embryonic kidney cells, was evaluated through MTT assay to roughly predict the 
toxicity profile of both everolimus and AZA in a non-cancer cell model. Combined treatment 
with everolimus and AZA, at concentrations showing synergistic antiproliferative activity in 
MZ-CRC-1 cells, inhibited viability of HEK-293 cells (- 25%) to a lesser extent than that 
detected in MTC cells (-54%) (figure 2A). Moreover, we did not observe any change in 
morphology of HEK-293 cells after treatment with everolimus and AZA compared to 
untreated control (figure 2B).  
 
 
3.3 Effects of everolimus and AZA on cell cycle. 
AZA alone slightly, but signiﬁcantly decreased cell population in G0/G1 phase (-6% vs 
untreated control, p<0.05) and increased cell number in G2/M phase (+23% vs untreated 
control, p<0.01), suggesting a cell cycle arrest in G2/M phase (figure 3). Everolimus alone 
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significantly decreased cells percentage in both S (-24% vs untreated control, p<0.05) and 
G2/M phase (-15% vs untreated control, p<0.05). This effect was comparable to that observed 
during the synergistic combination of everolimus plus AZA (S phase: -27% vs untreated 
control, G2/M phase: -14% vs untreated control, both p<0.05, figure 3).  
 
 
3.4 Effects of everolimus and AZA on apoptosis 
Everolimus did not change the percentages of early apoptotic and late apoptotic/necrotic cells 
compared with the untreated control. AZA induced a not statistically significant increase in 
the population of late apoptotic/necrotic cells. Interestingly, the AZA/everolimus 
combination significantly increased the percentage of early apoptotic (+35 % vs control, 
p<0.05) and late apoptotic/necrotic (+90% vs control, p<0.001) cells (figure 4A).  
Western blot analysis of key executioners of apoptosis, such as caspase-3 and poly(ADP-
ribose) polymerase (PARP) further confirmed these data (figure 4 B, C). After 6 days of 
treatment, the AZA/everolimus combination significantly increased caspase-3 degradation, 
resulting in increased expression of cleaved caspase-3 and decreased expression of full 
caspase-3. A moderate increase in cleaved caspase-3 has been detected after AZA alone. 
Similarly, the activity of PARP was moderately stimulated after 6 days of treatment with 
AZA, and its combination with everolimus enhanced again this effect. No significant changes 
in caspase-3 activity and PARP cleavage were detected after the incubation of MZ-CRC-1 
cells with everolimus alone.  
 
 
3.5 Effects of everolimus and AZA on mTOR activation 
No detectable impact on total mTOR and 4E-BP1 protein levels has been observed during 
incubation with everolimus and/or AZA in MZ-CRC-1 cells (figure 5). Everolimus alone 
significantly reduced both mTOR and 4E-BP1 phosphorylation. A similar effect has been 
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observed after everolimus in combination with AZA, while AZA alone did not significantly 
affect this process (figure 5). 
 
 
3.6 Gene Expression analysis 
To clarify the molecular bases for synergy between these two compounds, gene-expression 
proﬁles with or without everolimus and/or AZA treatment were evaluated in MZ-CRC-1 
cells. Following treatment with everolimus or AZA alone, 72 DEGs (supplementary table 1) 
and 16 DEGS (supplementary table 2) were identified, respectively. On the other hand, 74 
DEGs were identified following incubation with everolimus and AZA (supplementary table 
3). 
On each list of DEGs, a pathway analysis was performed with SPIA, which calculated the 
connections of pathways by considering their topology and the expression levels of their 
genes. Only for the comparisons between everolimus vs control and AZA/everolimus 
combination vs control significant pathways were detected (table 2 and 3). The significant 
pathways modulated after everolimus treatment (table 2) were PI3K-Akt signaling pathway 
and complement and coagulation cascades. SPIA analysis revealed four significant pathways 
in the group treated with the synergistic AZA/everolimus combination (table 3): PI3K-Akt 
signaling, neurotrophin signaling pathway, ECM-receptor interaction and focal adhesion. 
The module network obtained by the fusion of the four significant pathways in the group 
treated with the AZA/everolimus combination is described in figure 6. Edges represent 
interactions between two genes. The list of genes in the module is reported in supplementary 
table 4. All the DEGs reported in figure 6 were overexpressed compared to the untreated 
control. The SEM multi-group analysis was performed comparing the covariance matrices 
implied by the model for the treatment data against the control data. The likelihood ratio test 
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had a p-value of 0.002, confirming that the module was differentially regulated between the 
groups. The perturbed connections identified in this module are reported in the table 4.  
Considering the perturbed edges (table 4), the links between the NGFR and BAX resulted 
significant and intriguing because involved in the process of apoptosis (figure 6). NGFR was 
overexpressed during exposure to the AZA/everolimus combination compared to untreated 
control. In the same condition, the activation of RAC1 (mediated by NGFR) and the indirect 
interaction RAC1/MAPK10 resulted to be stimulated (table 4). It has been previously 
reported that the activation of MAPK10 (JNK3), mediated by NGFR/RAC1, can induce 
apoptosis through the increased expression of TP53 and BAX (Aloyz et al., 1998; Kenchappa 
et al., 2010). Although, in our model the path TP53→BAX was not significantly perturbed 
during incubation with the AZA/everolimus combination, an increase in BAX expression was 
detected during synergistic treatment. 
 
The same procedure was applied for the two pathways (table 2) previously identified during 
everolimus treatment. The directed shortest paths between the DEGs in the significant KEGG 
pathways generated the module reported in supplementary figure 1. The list of genes in the 
module is described in supplementary table 5. SEM was used to verify if globally the strength 
of connections was statistically different between control and everolimus in the assessed 
modules, but significant differences were not detected (p-value: 0.1144). Therefore, 
additional analyses were not performed. 
An enrichment analysis based on Disease Ontology terms was performed on the genes 
selected in the module related to the treatment with “everolimus plus AZA” (figure 7). 
Twenty-four out of 25 identified terms were tumors.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
3.7 Validation of gene expression data 
From the final model of perturbed biological pathways during concomitant incubation with 
AZA/everolimus combination (figure 6), NGFR-MAPK10-TP53-Bax/Bcl-2 pathway was 
selected for further analysis on the basis of its strict interaction and modulation of apoptosis, 
and assessed by western blot (figure 8). Indeed, in our system apoptosis was the cell death 
mechanism responsible for the synergistic cytotoxic activity of everolimus plus AZA.  
A significant increase in NGFR expression has been observed exclusively after 6 days of 
treatment with the synergistic combination of everolimus plus AZA in MZ-CRC-1 cells 
compared to untreated cells (figure 8). Everolimus and AZA alone and in combination 
increased the protein expression of MAPK10 and phosphorylated MAPK8/9/10, these effects 
were more pronounced with the combined treatment. In addition, a significant increase in 
phosphorylated p53 was observed only after incubation with everolimus and AZA 
combination (figure 8). The pro-apoptotic and anti-apoptotic Bax and Bcl-2, respectively, 
represent the key proteins involved in mitochondrial pathway of apoptosis. Western blot 
analysis showed that only the synergistic combination of everolimus plus AZA significantly 
increased Bax with a concomitant decrease in Bcl2 expression, while there was no significant 
change in the expression of these proteins after the exposure of MZ-CRC-1 cells to 
everolimus or AZA alone (figure 8).  
To verify that the synergistic antitumor activity observed during AZA/everolimus co-
incubation was indeed due to the increased expression in NGFR, we assessed the effects of 
both drugs alone or in combination on MZ-CRC-1 cells proliferation and protein expression 
of Bax and Bcl-2 after 6 days of treatment, in the presence or absence of a neutralizing 
antibody raised against NGFR (figure 9). The concomitant incubation with blocking NGFR 
antibody counteracted the cytotoxic activity of everolimus and AZA alone, and induced a 
moderate stimulation in cell proliferation after treatment with AZA/everolimus combination 
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(+20% vs control, p<0.01, figure 9A). In a parallel set of experiments performed without the 
incubation with neutralizing antibody against NGFR, the more potent antiproliferative 
activity after incubation with everolimus plus AZA has been confirmed compared to single 
drugs (figure 9B). During concomitant incubation with neutralizing antibody against NGFR, 
everolimus plus AZA induced a significant decrease in Bax and increase in Bcl-2 expression, 
while these effects were mild with each drug alone (figure 9C, D). 
 
3.8 Effects of everolimus and AZA on DNA methylation profile  
Methylation levels of genes identified in the perturbed everolimus plus AZA module (figure 
6 and supplementary table 4) were extrapolated from genome-wide methylation analysis 
using the Infinium HumanMethylation 450K BeadChip array performed in MZ-CRC-1 with 
or without treatment with everolimus and/or AZA. The array covers 769 probes for these 
selected 31 genes. Methylation levels for these genes resulted significantly different among 
groups (p=3.6x10
-5
) (supplementary figure 2A). A significant reduction in DNA methylation 
levels has been observed after incubation with AZA alone, similar to that observed after AZA 
plus everolimus compared to untreated control. The incubation with everolimus alone did not 
significantly modify DNA methylation levels. These data were confirmed through the density 
plot showing methylation level distributions of untreated and treated samples (supplementary 
figure 2B). A simile trend has been observed for NGFR and MAPK10, both methylated genes 
involved in the NGFR-MAPK10-TP53-Bax/Bcl-2 pathway (supplementary figure 2C). 
 
4. Discussion 
Aberrant promoter methylation of tumor suppressor genes plays a relevant role in the 
initiation and progression of cancer. In addition, it is being increasingly recognized that 
aberrant DNA methylation seems to be involved in the development of drug resistance 
through transcriptional suppression of genes implicated in drug metabolism, apoptosis, cell 
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cycle control, and other biological processes (Hervouet et al., 2013). Taking into 
consideration that DNA methylation is a reversible event unlike genetic mutations, the use of 
demethylating agents has been recently proposed as a new therapeutic strategy in cancer. 
Several reports demonstrated the capability of AZA to overcome resistance to 
chemotherapeutic and biological agents in tumors (Oronsky et al., 2014; Vijayaraghavalu et 
al., 2013; Zhang et al., 2009). This was encouraging, given that AZA is clinically used for 
patients with acute myeloid leukemia and myelodysplastic syndromes. 
In the current study, combination analysis, based on the Chou-Talalay's method, definitely 
demonstrated that AZA combined with everolimus was more effective in inhibiting cell 
proliferation than each agent alone in MTC cells. This cytotoxic activity was highly 
synergistic through a potent induction of apoptosis in MZ-CRC-1 cells, which was the cell 
line most resistant to everolimus alone. Whereas, in TT cells combined treatment exhibited 
both synergistic or antagonistic effects on cell proliferation inhibition, depending on the 
concentration of the drugs. In MZ-CRC-1 cells, while everolimus or AZA alone were barely 
effective in apoptosis induction, the AZA/everolimus combination doubled the fraction of 
MTC apoptotic cells compared to untreated controls. Cell-cycle analysis showed that 
everolimus decreased the percentages of MZ-CRC-1 cells in G2/M and S phase, but the 
combination with AZA did not potentiate this effect. Interestingly, the concentrations of AZA 
and everolimus adopted in vitro for the synergistic antiproliferative activity can be readily 
achieved in vivo with acceptable risk-benefit (O'Donnell et al., 2008; van Groeningen et al., 
1986). In addition, the in vitro toxicity of this combination appeared to be moderate. The 
cytotoxic activity of everolimus and AZA was lower in HEK-293 cells, a human embryonic 
kidney normal cell line, compared to that observed in MZ-CRC-1 cells. This is very 
promising in terms of safety and tolerability for future clinical trials.  
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Synergistic antiproliferative activity between AZA and everolimus was not related to a direct 
effect on mTOR activation. In fact AZA was unable to potentiate the inhibitory activity of 
everolimus on both mTOR and 4E-BP1 phosphorylation in MZ-CRC-1 cells.   
 
Gene expression analysis revealed potential molecular mechanisms implicated in the synergy 
of AZA and everolimus in MZ-CRC-1 cells. We adopted an innovative bioinformatic 
pipeline based on SPIA and SEM, recently validated by one of us (Pepe and Grassi, 2014), 
that allowed to investigate pathway modules, considering not only deregulated genes but also 
the connections between the perturbed ones. Several key regulatory genes modulated by the 
combined treatment of AZA plus everolimus were identified by this approach: PI3K-Akt 
signaling, neurotrophin signaling pathway, ECM-receptor interaction and focal adhesion. 
Interestingly, all these pathways have a critical role in the regulation of both proliferation and 
migration/invasion of tumor cells. In addition, a Disease Ontology enrichment analysis, 
performed on these selected genes, identified 25 biological terms. Twenty-four out of 25 
identified terms were tumors, including endocrine gland cancer. The only non-cancer item 
was “autosomal dominant disease”. These data further support the pivotal roles of these 
pathways in the development and progression of MTC. Indeed, MTC is a neuroendocrine 
tumor and MZ-CRC-1 cells harbor the Multiple Endocrine Neoplasia type 2B RET-M918T 
mutation, transmitted in this disease as an autosomal dominant trait (Santoro et al., 1995). 
 
A perturbed pathway module, associated to the combined treatment of everolimus plus AZA, 
was generated by the detection and fusion of all shortest paths that put in communication the 
DEGs (figure 6). In this network, the “neurotrophin signaling pathway” appeared to exert a 
direct influence on the apoptotic machinery through the overexpression of NGFR and the 
activation of MAPK10-TP53-Bax pathway. Neurotrophins are a family of proteins involved 
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in differentiation, plasticity and survival of neurons and modulating several functions of the 
neuroendocrine-immune system (Fiore et al., 2009). This family includes nerve growth factor 
(NGF), brain derived neurotrophic factor (BDNF), neurotrophins-3 (NT-3), neurotrophins-
4/5 (NT-4/5) and neurotrophins-6 (NT-6). Biological activity of these factors is mediated 
through activation of Trk tyrosine kinase receptors (TrkA, TrkB, and TrkC) and NGFR (also 
known as p75 neurotrophin receptor, p75NTR) (Skaper, 2012). In our study, gene expression 
analysis confirmed the induction of apoptosis through the upregulation of Bax. Bax is a pro-
apoptotic protein antagonized by the antiapoptotic Bcl-2. The ratio of Bax to Bcl-2 
expression represents a cell death switch, which determine the susceptibility of cells to an 
apoptotic stimulus. Indeed, a selective decrease in Bax/Bcl-2 expression represents a 
common mechanism of drug resistance in tumor cells (Indran et al., 2011). We have found a 
selective increase in the expression of Bax/Bcl-2 ratio, validated through WB analysis, 
exclusively after treatment with AZA and everolimus. This effect seems to be associated with 
the upregulation of NGFR, which has been described to be a tumor-suppressor gene in 
several tumors (Dimaras and Gallie, 2008; Jin et al., 2007; Khwaja et al., 2004; Khwaja et al., 
2006; Kuchler et al., 2011; Kuner and Hertel, 1998; Wang et al., 2014; Yang et al., 2015; 
Yuanlong et al., 2008), and consecutive activation of MAPK10 and p53.  
 
Although the specific role of NGFR in the tumorigenesis and progression of MTC is 
unknown, neurotrophin signaling pathway appears to be involved in both preneoplastic 
thyroid C cell hyperplasia and MTC progression through Trk receptors (McGregor et al., 
1999). In fact, a cross-talk between the signal pathways mediated by the Ret protoncogene 
and Trk receptors has been described (Esposito et al., 2008; Peterson and Bogenmann, 2004). 
The concomitant incubation with blocking NGFR antibody counteracted the cytotoxic 
activity of everolimus and AZA alone, and induced a moderate stimulation in cell 
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proliferation and a decrease in Bax/Bcl-2 ratio expression after treatment with AZA plus 
everolimus compared to control. This effect could be explained by the block of the pro-
apoptotic pathway mediated by NGFR, while the survival pathways remained activated. 
These data confirmed that the NGFR overexpression plays a main role in the synergistic 
cytotoxic activity of these two compounds. Although the mechanism by which the expression 
of NGFR significantly increased during incubation with everolimus and AZA remains 
unclear, in colorectal cancer it has been recently reported that NGFR expression was silenced 
by promoter methylation and that the overexpression of this gene signiﬁcantly inhibited cell 
proliferation, invasion and stimulated cell apoptosis (Yang et al., 2015). In our model the 
overexpression of NGFR appears not to be related to a direct epigenetic effect on NGFR 
gene. In fact, during incubation of MZ-CRC-1 cells with AZA, we found a significant 
decrease in DNA methylation levels of NGFR, comparable to that observed after everolimus 
plus AZA, while NGFR expression increased exclusively after combined treatment. 
Intriguingly, the synergistic cytotoxic activity of everolimus/AZA combination was more 
relevant in MZ-CRC-1 (harboring RET-M918T mutation) than in TT (harboring RET-
C634W mutation) cells (Table 1). We cannot exclude that the type of RET genetic alteration 
may have a role in the different antitumor activity observed in both cell lines. In fact, Gild et 
al. (2013) demonstrated that oncogenic RET regulates mTOR activity in MZ-CRC-1 and TT 
cell lines. Combined incubation with RET and mTOR inhibitors (AST487 and INK128, 
respectively) at low concentrations cooperated to inhibit mTOR signaling and cell growth, 
through induction of apoptosis, in both MTC cell lines. In addition, a recent study found that 
methylation profiles relate closely to RET mutational status in MTC, and the most distinctive 
methylome was observed for RET-M918T positive tumors (Mancikova et al., 2017). 
In conclusion, we described for the first time a synergistic cytotoxic activity combining AZA 
with everolimus in MTC. This effect occurred through the overactivation of NGFR-
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MAPK10-TP53-Bax/Bcl-2 pathway and the induction of apoptosis. These data provide a new 
therapeutic scenario in MTC and probably in other neuroendocrine tumors, where therapy 
with everolimus is currently approved. 
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Table 1: Combination index (CI), dose reduction index (DRI) and potentiation factor 
(PF), according to the different cytotoxic ratio of everolimus (EV) and 5-aza-2′-
deoxycytidine (AZA) combination in MZ-CRC-1 and TT cell lines after 6 days of 
treatment. 
1CI50 was calculated for 50% cell survival (ED50) by isobologram analyses performed with CalcuSyn software. 
2DRI was calculated in case of synergism. It represents the order of magnitude (fold) of dose reduction obtained 
for ED50 effect in combination setting as compared to each drug alone. 
3PF was calculated in case of synergism as the ratio between the IC50 of either everolimus or AZA alone and the 
IC50 of everolimus or AZA in combination setting. 
 
 
           
Cell line Cytotoxic 
ratio 
ED
50 (nM) CI
50
1
 DRI50
2
  PF
3 Interpretation 
  EV AZA  EV AZA  EV AZA  
           
           
MZ-CRC-1 EV-AZA 
(50:50) 
 
12.4 35.6 0.2 4.3 5.9x102  1.8 1.1x103 Strong 
synergism 
 EV-AZA 
(25-75) 
 
2.1 1.4x102 0.1 8.8 1.0x102  10.4 2.8x102 Strong 
synergism 
 EV-AZA 
(75-25) 
1.3x102 3.2x10-1 2.3 − −  − − Antagonism 
           
TT EV-AZA 
(50:50) 
 
9.2 3.4x10-1 1.3 − −  − − Antagonism 
 EV-AZA 
(25-75) 
 
1.2 8.0 0.7 1.5 6.4x102  6.1 11 Synergism 
 EV-AZA 
(75-25) 
91.1 1.2x10-3 17 − −  − − Antagonism 
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Table 2. Significant pathways associated to treatment with everolimus by SPIA in MZ-
CRC-1 cells 
pPERT: probability of observing a total accumulated perturbation of the pathway more extreme than expected 
by chance; pNDE: probability of obtaining a number of DEGs in the given pathway at least as large as the 
observed one; pGFdr: false discovery rate for the global p-value from the combination of pPERT and pNDE. 
 
 
Pathway Name 
 
pPERT 
 
pNDE 
 
pGFdr 
    
PI3K-Akt signaling pathway 0.066 0.0013 0.036 
Complement and coagulation cascades 0.493 0.0005 0.048 
 
Table 3. Significant pathways associated to treatment with everolimus plus AZA by 
SPIA in MZ-CRC-1 cells 
pPERT: probability of observing a total accumulated perturbation of the pathway more extreme than expected 
by chance; pNDE: probability of obtaining a number of DEGs in the given pathway at least as large as the 
observed one; pGFdr: false discovery rate for the global p-value from the combination of pPERT and pNDE. 
 
 
Pathway Name pPERT pNDE pGFdr 
    
PI3K-Akt signaling pathway 0.102 0.0002 0.0178 
Neurotrophin signaling pathway 0.689 0.0002 0.0308 
ECM-receptor interaction 0.115 0.0013 0.0308 
Focal Adhesion 0.199 0.0018 0.0415 
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Table 4. Perturbed connections in the everolimus plus AZA module compared to the 
untreated control. The estimation of the strength connection and p-value for “Control”, 
“everolimus plus AZA” and the “difference between everolimus plus AZA vs control” 
are reported. We have only included the connections where a significant statistical P 
value has been observed for the “difference between everolimus plus AZA vs control”. 
 
     
  Control Everolimus + AZA Difference 
Path Type of process Estimate 
P 
value 
Estimate P value Estimate P value 
        
MDM2→TP53 Inhibition 0.8271 0.0001 -0.9864 0.0022 -1.8135 0.0000 
NGFR→ARHGDIB Binding/association 0.8935 0.0001 2.7208 0.0001 1.8273 0.0125 
EPHA2→IRS1 Activation -0.5077 0.0079 0.3521 0.2699 0.8598 0.0208 
PIP5K1C→VCL Indirect -0.6464 0.0237 0.3072 0.0001 0.9536 0.0013 
VCL→ACTN1 Binding/association -0.0985 0.8827 2.4853 0.0002 2.5839 0.0062 
ITGA1→PTK2 Binding -0.3282 0.0206 0.1908 0.2790 0.5190 0.0218 
NGFR→RAC1 Activation -0.9042 0.0180 0.5223 0.0155 1.4265 0.0012 
RAC1→MAPK10 Indirect 0.0499 0.6359 0.5799 0.0001 0.5300 0.0033 
NGFR→CDC42 Activation 0.2736 0.3068 -1.0567 0.0001 -1.3303 0.0004 
PAK1→MAP2K1 Phosphorylation 0.4008 0.0018 -0.0669 0.0998 -0.4678 0.0005 
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FIGURE LEGENDS 
 
Figure 1. Evaluation of synergism between everolimus (EV) and 5-aza-2’deoxycytidine 
(AZA) in medullary thyroid cancer cells by isobologram analysis. These experiments were 
performed with MTT assay. Combination index (CI)/fractional effect curves were elaborated 
with the dedicated software Calcusyn (developed by Chou and Talalay) as described in 
Materials and methods. Curves show the CI vs the fraction of medullary thyroid carcinoma 
cells MZ-CRC-1 (A-C) and TT (D-F) affected by the EV-AZA combinations at 50:50 (A/D), 
25:75 (B/E), 75:25 (C/F) cytotoxic ratios. CI represent the assessment of synergy induced by 
drug interaction. In detail, CI values of <1, 1, and >1 indicate synergy, additivity, and 
antagonism, respectively. Each point (represented in graph by x-mark) is the mean of at least 
4 different replicates. The statistical significance of each point was evaluated with ANOVA 
and the derived p values were always less than 0.01. 
 
Figure 2. In vitro toxicity profile of everolimus (EV) and 5-aza-2’deoxycytidine (AZA). 
Cells were treated for 6 days with EV (2.1 nM) and/or AZA (1.4x10
2
 nM). (A) The 
cytotoxicity was measured by MTT cell viability assay in HEK-293 and MZ-CRC-1 cell 
lines. (B) The morphology of HEK-293 cells was determined after 6 days of exposure to drug 
free medium (CTR) and EV plus AZA. Images were captured using a phase-contrast 
microscopy at x 20 magnification.***p<0.001.  
 
Figure 3: Cell cycle distribution, detected by FACS analysis, in propidium iodide stained 
MZ-CRC-1 cells after 6 days of treatment with 2.1 nM everolimus (EV) and/or 1.4x10
2
 nM 
5-aza-2’deoxycytidine (AZA). Control values have been set to 100%. *p<0.05  ** p<0.01 
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Figure 4: Effects of 2.1 nM everolimus (EV) and/or 1.4x10
2
 nM 5-aza-2’deoxycytidine 
(AZA) on apoptosis in MZ-CRC-1 cells after 6 days of incubation. (A) Flow cytometry with 
Annexin V and propidium iodide. Values of early apoptotic cells and late apoptotic/necrotic 
cells were expressed as percentage compared with the untreated control. (B) Representative 
western blot analysis of apoptotic markers (full and cleaved forms of caspase 3 and PARP). 
Actin was used as a loading control. (C) Quantification of western blot analysis from at least 
three independent experiments. *p<0.05;  ** p<0.01; *** p<0.001 
 
Figure 5: Effects of 2.1 nM everolimus (EV) and/or 1.4x10
2
 nM 5-aza-2’deoxycytidine 
(AZA) on protein expression of total and phosphorylated mTOR and 4E-BP1 in MZ-CRC-1 
cells after 6 days of incubation. (A) Representative western blot analysis. Actin was used as a 
loading control. (B) Quantification of western blot analysis from at least three independent 
experiments. *p<0.05;  ** p<0.01  
 
Figure 6. Perturbed pathway module in the group treated with everolimus and 5-aza-
2’deoxycytidine. The green nodes are the DEGs, the yellow nodes represent the not DEGs 
microarray genes that connect the DEGs. Edges represent interactions between two genes. 
 
Figure 7. Disease ontology enrichment analysis for the genes selected in the significant 
perturbed module, in the group treated with everolimus and 5-aza-2’deoxycytidine. 
 
Figure 8. (A) Representative western blot analysis of NGFR, MAPK10, phosphorylated 
MAPK8/9/10, phosphorylated p53, Bax and Bcl-2 performed in MZ-CRC-1 cells without 
(CTR) or after incubation with 2.1 nM everolimus (EV) and/or 1.4x10
2
 nM 5-aza-
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2’deoxycytidine (AZA). Actin was used as a loading control. (B) Quantification of western 
blot analysis from at least three independent experiments. *p<0.05;  ** p<0.01; *** p<0.001 
 
Figure 9: Effect of 2.1 nM everolimus (EV) and/or 1.4x10
2
 nM 5-aza-2’deoxycytidine 
(AZA) on cell proliferation in MZ-CRC-1 cells (A, B) and protein expression of Bax and 
Bcl-2 (C, D)  after 6 days of treatment, in the presence (A, C, D) or absence (B) of 
neutralizing antibody against NGFR (1:250). (C) Representative western blot analysis. Actin 
was used as a loading control. (D) Quantification of western blot analysis from at least three 
independent experiments. *p<0.05; p<** p<0.01; *** p<0.001 
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